OnCo
peoplePerson

Mark R. Litzow

Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.

Hematologist who chaired ECOG-ACRIN E1910, showing blinatumomab consolidation improves survival in MRD-negative B-ALL, leading to a 2024 label change.

Role
Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910
Institution
Mayo Clinic
Specialisms
Acute lymphoblastic leukaemiaImmunotherapyTransplant

Papers

2top
TitleJournalYear
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsNew England Journal of Medicine2024
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemiaBlood2010

Key papers

1top
rctNew England Journal of Medicine 2024changed practice
ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission

E1910 changed the standard of care for adult B-ALL: immunotherapy is now part of front-line consolidation even for patients with no detectable leukaemia, because MRD-negative by flow cytometry does not mean cured. It also demonstrated that a T-cell engager can improve overall survival in a curative setting. Chemotherapy-light or chemotherapy-free regimens built on blinatumomab and inotuzumab are the next step.

Connected

8top

cancers

1
Acute lymphoblastic leukaemia

targets

2
CD19CD3

drugs

1
ApprovedBispecific T-cell engager (CD19×CD3)
Blinatumomab · Blincyto

institutions

2
ECOG-ACRIN Cancer Research GroupMayo Clinic

trials

1
ECOG-ACRIN E1910

key papers

1
ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission